Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gyorki

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Annals of Surgical Oncology|April 17, 2022
Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?David E Gyorki
Journal of Oncology Practice|May 11, 2018
Management of In-Transit Melanoma: We Need Some High-Quality DataDavid E Gyorki
ANZ Journal of Surgery|April 21, 2005
Laudable pus: historic concept revisitedDavid E Gyorki
Annals of Surgical Oncology|June 23, 2019
ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of LifeSarah Banting, David E Gyorki
The Lancet. Oncology|May 14, 2021
Second-line immunotherapy in patients with metastatic melanomaAnnie Wong, David E Gyorki
Annals of Surgical Oncology|August 9, 2025
ASO Author Reflections: Retroperitoneal PEComas: Defining Risk by Subtype and the Need for Centralized Sarcoma ExpertiseEyal Mor, David E Gyorki
ANZ Journal of Surgery|June 5, 2008
Macrophages, more than just scavengers: their role in breast development and cancerDavid E Gyorki, Geoffrey J Lindeman
Melanoma Management|December 7, 2019
An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?Jennifer S Downs, David E Gyorki
The Medical Journal of Australia|October 22, 2014
Sentinel lymph node biopsy for melanoma: an important risk-stratification toolDavid E Gyorki, Michael A Henderson
Journal of Surgical Oncology|October 25, 2013
Management of recurrent retroperitoneal sarcomaDavid E Gyorki, Murray F Brennan
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Annals of Surgical Oncology|April 17, 2022
Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?David E Gyorki
Journal of Oncology Practice|May 11, 2018
Management of In-Transit Melanoma: We Need Some High-Quality DataDavid E Gyorki
ANZ Journal of Surgery|April 21, 2005
Laudable pus: historic concept revisitedDavid E Gyorki
Annals of Surgical Oncology|June 23, 2019
ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of LifeSarah Banting, David E Gyorki
The Lancet. Oncology|May 14, 2021
Second-line immunotherapy in patients with metastatic melanomaAnnie Wong, David E Gyorki
Annals of Surgical Oncology|August 9, 2025
ASO Author Reflections: Retroperitoneal PEComas: Defining Risk by Subtype and the Need for Centralized Sarcoma ExpertiseEyal Mor, David E Gyorki
ANZ Journal of Surgery|June 5, 2008
Macrophages, more than just scavengers: their role in breast development and cancerDavid E Gyorki, Geoffrey J Lindeman
Melanoma Management|December 7, 2019
An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?Jennifer S Downs, David E Gyorki
The Medical Journal of Australia|October 22, 2014
Sentinel lymph node biopsy for melanoma: an important risk-stratification toolDavid E Gyorki, Michael A Henderson
Journal of Surgical Oncology|October 25, 2013
Management of recurrent retroperitoneal sarcomaDavid E Gyorki, Murray F Brennan
Pageof 12